Genocea Biosciences, Inc. (NASDAQ:GNCA) released its earnings results on Thursday. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.08), Briefing.com reports. During the same period in the previous year, the business earned ($0.45) EPS.

Genocea Biosciences (GNCA) traded down $0.05 during trading on Friday, reaching $1.05. 860,382 shares of the company were exchanged, compared to its average volume of 900,278. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.97 and a quick ratio of 2.97.

TRADEMARK VIOLATION WARNING: This piece was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/03/genocea-biosciences-inc-gnca-announces-earnings-results.html.

A hedge fund recently bought a new stake in Genocea Biosciences stock. California State Teachers Retirement System bought a new stake in Genocea Biosciences, Inc. (NASDAQ:GNCA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 50,700 shares of the biotechnology company’s stock, valued at approximately $265,000. California State Teachers Retirement System owned approximately 0.18% of Genocea Biosciences at the end of the most recent quarter. 57.39% of the stock is owned by institutional investors.

A number of analysts recently weighed in on the stock. Piper Jaffray Companies reissued an “overweight” rating and issued a $5.00 target price on shares of Genocea Biosciences in a research note on Thursday. Needham & Company LLC raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Monday, July 24th. Cowen and Company reiterated an “outperform” rating and set a $40.00 target price on shares of Genocea Biosciences in a research report on Tuesday, July 25th. ValuEngine lowered shares of Genocea Biosciences from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 26th. Finally, Stifel Nicolaus lowered shares of Genocea Biosciences from a “buy” rating to a “hold” rating and cut their price objective for the company from $15.00 to $2.50 in a report on Monday, September 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $7.62.

About Genocea Biosciences

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Earnings History for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.